Playback speed
10 seconds
ASCO® 2023 Insights: "Expanding the Benefit - Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAFV600E+ Adult & Pediatric Solid Tumors"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Vivek Subbiah
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Vivek Subbiah
1,236 views
July 6, 2023
Vivek Subbiah, MD, now Chief of Early-Phase Drug Development for Sarah Cannon Research Institute (SCRI), ...
read more ↘ discusses the research conducted at The University of Texas MD Anderson Cancer Center, Houston, TX.
↖ read less
read more ↘ discusses the research conducted at The University of Texas MD Anderson Cancer Center, Houston, TX.
↖ read less
Comments 0
Login to view comments.
Click here to Login